Daphnetin

Daphnetin is a natural coumarin derivative (7,8-dihydroxycoumarin) extracted primarily from Daphne species plants, acting as a potent inhibitor of protein kinases and cyclooxygenase enzymes. Its primary mechanisms involve suppression of NF-κB signaling and free radical scavenging, driving its anti-inflammatory and antioxidant properties observed in preclinical research.

Origin & History

Daphnetin is a dihydroxycoumarin derived from plants in the Daphne genus, including Daphne mezereum and Euphorbia lathyris. It is extracted using solvents like ethanol and methanol from plant parts such as leaves and stems.

Historical & Cultural Context

Daphne species have been used in traditional medicine for their anti-inflammatory and uric acid excretion effects. Daphnetin was first isolated in 1820 and appears in Chinese medicinal herbs.

Health Benefits

• Anti-inflammatory effects: Demonstrated in preclinical studies, though no human trials confirm efficacy. • Antioxidant properties: Shown in animal models, with no direct clinical evidence. • Neuroprotective benefits: Observed in vitro, lacking human trial confirmation. • Hepatoprotective effects: Noted in animal studies, without human data. • Anti-cancer potential: Indicated in preclinical research, but lacks clinical validation.

How It Works

Daphnetin (7,8-dihydroxycoumarin) inhibits protein kinase activity, particularly CaM kinase II and several receptor tyrosine kinases, disrupting downstream inflammatory cascades. It suppresses NF-κB nuclear translocation, reducing transcription of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, while also inhibiting COX-1 and COX-2 enzyme activity to limit prostaglandin synthesis. Its catechol-like dihydroxy structure on the benzene ring confers direct free radical scavenging capacity and Nrf2 pathway activation, supporting antioxidant enzyme upregulation including superoxide dismutase and catalase.

Scientific Research

No human clinical trials or meta-analyses for daphnetin were identified. Evidence is limited to preclinical studies focusing on its pharmacological potential.

Clinical Summary

The vast majority of daphnetin research consists of in vitro cell studies and rodent models, with no robust randomized controlled human trials published as of 2024. Animal studies in murine models of arthritis demonstrated significant reductions in paw swelling and inflammatory cytokine levels at doses ranging from 10–40 mg/kg, but these findings have not been translated to human pharmacokinetic or efficacy data. Neuroprotective effects have been observed in rat models of cerebral ischemia-reperfusion injury, showing reduced infarct volume and oxidative stress markers, while hepatoprotective activity was demonstrated in carbon tetrachloride-induced liver injury models with improved AST and ALT enzyme profiles. The overall evidence base remains preclinical, and claims of human therapeutic benefit are not currently supported by clinical trial data.

Nutritional Profile

Daphnetin (7,8-dihydroxycoumarin) is a pure bioactive coumarin compound, not a whole food ingredient, and thus lacks conventional macronutrient or micronutrient content. Molecular weight: 178.14 g/mol. Molecular formula: C9H6O4. It is not a source of protein, fat, dietary fiber, carbohydrates, vitamins, or dietary minerals in any nutritional sense. Primary bioactive identity: a naturally occurring coumarin derivative isolated predominantly from plants of the genus Daphne (e.g., Daphne odora, Daphne genkwa) and Wikstroemia indica. Bioactive compound concentration in source plants: daphnetin content in Daphne species bark and root extracts ranges approximately 0.1–2.5 mg/g dry weight depending on plant part and extraction method. As an isolated compound, it is studied in concentrations of 10–100 µM in vitro and 10–50 mg/kg body weight in rodent in vivo models. Bioavailability notes: oral bioavailability is reported as moderate to low in animal pharmacokinetic studies, with rapid hepatic metabolism via glucuronidation and sulfation; peak plasma concentration (Cmax) reached within 0.5–2 hours post-administration in rodent models; half-life approximately 1–3 hours. Lipophilicity (logP) is approximately 1.0, suggesting moderate membrane permeability. No human pharmacokinetic data currently available. Not a dietary supplement ingredient with established human dosing.

Preparation & Dosage

No clinically studied dosage ranges are available due to the absence of human trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Curcumin, Resveratrol, Green Tea Extract, Black Pepper Extract

Safety & Interactions

Daphnetin has not been formally evaluated for safety in human clinical trials, making definitive side effect profiling impossible at this time. In animal studies, high-dose administration has been associated with mild hepatic stress markers, and its potent kinase-inhibitory properties raise theoretical concerns about interactions with anticoagulant medications such as warfarin, given that many coumarins interfere with vitamin K-dependent clotting factors. Daphnetin's inhibition of CYP450 enzymes in vitro suggests potential for drug-drug interactions affecting the metabolism of statins, immunosuppressants, and other hepatically cleared compounds. Use during pregnancy or lactation is contraindicated due to the absence of safety data and the known uterotonic potential of some coumarin-class compounds.